Army Medical Department (United States)

Stop Our Stigma Campaign Aims to Normalize Seeking Mental Health Support for First Responders

Retrieved on: 
Thursday, July 27, 2023
Prejudice, University, Suicide, Firefighter, EMT, Assistant, University of Arizona College of Pharmacy, Organization, EMS, Army Medical Department (United States), City, Emergency medical technician, Empathy, Trauma, Mental health, Conference, Nursing, PHOENIX

PHOENIX, July 27, 2023 /PRNewswire-PRWeb/ -- EMSHelp.org, a non-profit organization committed to advancing suicide prevention among EMS providers, launched its "Stop Our Stigma" campaign on Wednesday, July 12 at the AFCA/AFDA Fire and EMS Leadership Conference and Expo 2023. Board members Rob Brewster and Dale Crogan were in attendance to request all attendees sign the pledge to "recognize and commit to reducing the stigma associated with mental health and seeking mental health help."

Key Points: 
  • EMSHelp.org and Arizona fire chiefs implore first responders to take the pledge to normalize seeking mental health help to reduce staggering suicide numbers.
  • Board members Rob Brewster and Dale Crogan were in attendance to request all attendees sign the pledge to "recognize and commit to reducing the stigma associated with mental health and seeking mental health help."
  • "We need to break that stigma and create a more compassionate society for all first responders struggling with mental health challenges."
  • All first responders are invited to join the mission to end the stigma associated with mental health and reduce the suicide rate.

Nation's Finest Welcomes Three New Veterans to National Board of Directors

Retrieved on: 
Monday, July 24, 2023
Sarge, San Francisco, Meritorious Service Medal (United States), American Red Cross, San Francisco Bay Area, Music, Finance system in Azerbaijan, Air force academy, Virginia House, University, Commendation Medal, Army, Defense, Nation, Meritorious Service Medal, 2023 Virginia House of Delegates election, University of California, San Francisco, United States Army Cavalry School, LNC, United States Air Force Academy, Federal, DNP, Army Medical Department, Federation, United States Cavalry, UCSF, National Board of Trial Advocacy, Love, Dog, NP, Diversity, Chairperson, Air force, Delegate, MPH, Department of Defence, Army Medical Department (United States), Management, Nursing, Finest, United States Army, Veteran

SANTA ROSA, Calif., July 24, 2023 /PRNewswire/ -- Nation's Finest, a national organization that serves Veterans, is pleased to announce it has added three new Veterans to its National Board of Directors.

Key Points: 
  • SANTA ROSA, Calif., July 24, 2023 /PRNewswire/ -- Nation's Finest, a national organization that serves Veterans, is pleased to announce it has added three new Veterans to its National Board of Directors.
  • In making the announcement, Nation's Finest CEO Chris Johnson said, "Nation's Finest is thrilled to introduce three highly accomplished U.S. veterans who have joined our Board of Directors.
  • "We are incredibly honored and excited to welcome these three outstanding veterans to our Board of Directors," said Philip Williams, Board Chair.
  • The governing Board of Directors at Nation's Finest currently has 13 Directors from various backgrounds, 11 of whom are veterans.

Chronic Kidney Disease: Breaking Barriers with Cardiovascular and Renal Integration in Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, June 7, 2023
Chronic kidney disease, Prevalence, Clinical trial management system, Cardiovascular disease, FACC, Clinical trial, Quality of life, Risk, History, Doctor of Philosophy, Thought, Army Medical Department (United States), Incidence, Patient, FASN, Mortality, Longevity, CKD, Conditional sentence, Pharmaceutical industry, MD, Medpace

TORONTO, June 7, 2023 /PRNewswire-PRWeb/ -- 21st century medicine and technology has seen exciting advancements at a pace and scale so remarkable that it exceeds the medical trajectory as compared to all of human history combined. This evolution, marked by preventative measures in healthcare, has improved the longevity and quality of life for patients, which also equates to a rising incidence and prevalence of chronic disease, especially chronic kidney disease (CKD).

Key Points: 
  • In this free webinar, learn about the historical exclusion of chronic kidney disease (CKD) from clinical trials and the considerations and reasons to increase the CKD population in clinical trials.
  • The featured speakers will discuss cardiorenal case studies to exemplify how cross collaboration and integration lead to overall clinical trial success.
  • Historically, however, those with chronic kidney disease have represented a population traditionally excluded from clinical trials, especially those in cardiovascular disease despite the improved understanding of its implications related to comorbid diseases.
  • Join this webinar to learn about integrated approaches to include patients with chronic kidney disease in cardiovascular clinical trials, benefiting both patients and improving disease burden worldwide.

Northwell Direct to Provide Telehealth Services to U.S. Department of State

Retrieved on: 
Wednesday, May 31, 2023
Professional Services, Health, Telemedicine, Virtual Medicine, Health Technology, Managed Care, General Health, Consulting, Emergency medicine, USG, Elective surgery, Pediatrics, DOS, Army Medical Department (United States), Federal government of the United States, Multimedia, Radiology, United, National Association Medical Staff Services, Dermatology, Direct, Neuroscience, MD, Bureau of Medical Services (U.S. Department of State), Cardiology, Psychiatry, Nursing, State, Northwell Health

Northwell Direct today announced that it has been selected as the subcontractor on a U.S. Department of State (DOS) contract to provide telehealth consult services to DOS medical providers serving U.S. Government (USG) employees and family members posted overseas.

Key Points: 
  • Northwell Direct today announced that it has been selected as the subcontractor on a U.S. Department of State (DOS) contract to provide telehealth consult services to DOS medical providers serving U.S. Government (USG) employees and family members posted overseas.
  • View the full release here: https://www.businesswire.com/news/home/20230531005777/en/
    Leveraging Northwell Health ’s extensive network of specialists, Northwell Direct will provide consultation services to DOS that will assist its medical staff around the world.
  • “Telemedicine is a unique area of opportunity for Northwell Direct to provide support and expertise to the Department of State,” said Jonathan Berkowitz, MD, medical director of center emergency medical services at Northwell Health.
  • “Northwell Direct is proud to be working with the United States Department of State and doing our part to ensure that the employees and family members who serve our country have access to the highest quality health care services while serving abroad,” said Nick Stefanizzi , Chief Executive Officer of Northwell Direct.

Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody Therapy CMTX-101 Against Community-acquired Bacterial Pneumonia

Retrieved on: 
Wednesday, November 30, 2022
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Army Medical Department (United States), Infection, Immune system, Pharmacokinetics, Bacteria, Patient, Mortality, Biomarker, FDA, Senior, Biofilm, MPH, Urinary tract infection, Vaccine, Gram-positive bacteria, Safety, Pharmaceutical industry, MD, Medpace

(Clarametyx), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced the initiation of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections.

Key Points: 
  • (Clarametyx), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced the initiation of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections.
  • The technology precisely and rapidly destroys the universal underlying structure of bacterial biofilms, which undermines bacterial defenses and enables more effective antibiotic and immune interventions.
  • The company will initiate a Phase 1a safety evaluation in healthy volunteers, evaluating up to four doses of CMTX-101.
  • Clarametyx and its collaborators are separately advancing preclinical assessments of this antibody technology as a possible preventative approach for other bacterial infections.

Radiation Toxicity -- Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 31, 2022
Bachelor of Science, Army Medical Department (United States), RN, Clinical trial, ARNP, MD, Radiation exposure, Solution, MA, Patient, Radiation, Toxicity, FNP, Industry, MBA, MS, Overalls, Pulmonary toxicity, Food, Doctor of Philosophy, Clinical trial management system, Data management, Probability, Pharmaceutical industry, Medical imaging, Honours degree, Medpace

TORONTO, Oct. 31, 2022 /PRNewswire-PRWeb/ -- As the radiopharmaceutical research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials. Conducting radiopharmaceutical trials presents a unique set of obstacles, such as the challenge of capturing unique radiation induced toxicities in the context of enrolled patients' overall radiation exposure. This requires an understanding of enrolled patients' cumulative radiation exposure from previous radiation treatments and current studies. For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.

Key Points: 
  • Conducting radiopharmaceutical trials presents a unique set of obstacles, such as the challenge of capturing unique radiation induced toxicities in the context of enrolled patients' overall radiation exposure.
  • This requires an understanding of enrolled patients' cumulative radiation exposure from previous radiation treatments and current studies.
  • For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.
  • For more information, or to register for this event, visit Radiation Toxicity Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials .

Achieving Successful Cell Therapy Outcomes through Integrated Expertise, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, September 29, 2022
Probability, MSN, MD, Clinical trial management system, Mistake, Industry, Army Medical Department (United States), Clinical trial, Doctor of Philosophy, Food, Research, APRN, Pharmaceutical industry, Medicine, Medpace

TORONTO, Sept. 29, 2022 /PRNewswire-PRWeb/ -- As the cell therapy research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials. Conducting cellular therapy trials presents a unique set of challenges, especially in early phase development. Successful preclinical to clinical transition requires careful planning with the aim of avoiding mistakes and surmounting barriers common to the development and operation of cell therapy trials.

Key Points: 
  • Attendees will learn from an investigational analysis of complex cell therapy studies.
  • TORONTO, Sept. 29, 2022 /PRNewswire-PRWeb/ -- As the cell therapy research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials.
  • Successful preclinical to clinical transition requires careful planning with the aim of avoiding mistakes and surmounting barriers common to the development and operation of cell therapy trials.
  • For more information, or to register for this event, visit Achieving Successful Cell Therapy Outcomes through Integrated Expertise .

Liquid Biopsy in Oncology: Opportunities and Challenges, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 18, 2022
FDA, Precision medicine, Industry, Senior, Neoplasm, FACS, Fluid mechanics, Technology, CTC, Clinical trial, Lists of diseases, Blood, Army Medical Department (United States), NSCLC, Patient, DNA, Large-cell lung carcinoma, Food, EGFR, NGS, Health, EV, Doctor of Philosophy, Circulating tumor DNA, US Foods, Liquid biopsy, Clinical trial management system, Disease, Antibiotics, Medical imaging, Medicine, MD

TORONTO, Aug. 18, 2022 /PRNewswire-PRWeb/ -- A liquid biopsy is a simple and non-invasive alternative to surgical biopsies. It has the potential to identify genetic abnormalities that may guide treatment selection as well as detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells (CTC), circulating tumor DNA (ctDNA), tumor extracellular vesicles (EV), etc., present in the body fluids of patients and using them to derive genomic and proteomic data. This reveals greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations and clonal evolution.

Key Points: 
  • TORONTO, Aug. 18, 2022 /PRNewswire-PRWeb/ -- A liquid biopsy is a simple and non-invasive alternative to surgical biopsies.
  • Technological innovation in liquid biopsy platforms and testing methodologies led to a rapid transformation of precision medicine in cancer care.
  • As a result, several liquid biopsy tests have been approved by the US Food and Drug Administration (FDA).
  • For more information, or to register for this event, visit Liquid Biopsy in Oncology: Opportunities and Challenges .

Imperative Care Appoints Henrietta Fore and Stacy Enxing Seng to Board of Directors

Retrieved on: 
Tuesday, June 21, 2022
Medical Supplies, Health, Medical Devices, Surgery, Health Technology, Cardiology, Biotechnology, USAID, Solution, Army Medical Department (United States), Department, Business administration, Stroke, World, Master of Business Administration, Moyamoya disease, Female, CEO, University of Northern Colorado, United, LivaNova, Woman, Degenerative disease, The arts, Knowledge, Henrietta H. Fore, Operating partner, UNICEF, Imperative, Gaps, Physician, Marketing, United States Mint, International development, University, ExxonMobil, Housing, Communities and Local Government Committee, Economics, PLC, World Health Organization, Harvard Business School, Board, Patient, Health, Art, General Mills, Public policy, Michigan State University, Wellesley College, Management, Medicine, History, Science

Imperative Care, Inc. today announced the appointment of Henrietta Fore and Stacy Enxing Seng to the companys Board of Directors, effective immediately.

Key Points: 
  • Imperative Care, Inc. today announced the appointment of Henrietta Fore and Stacy Enxing Seng to the companys Board of Directors, effective immediately.
  • The addition of Henrietta and Stacy to Imperative Cares Board of Directors will prove invaluable as they bring varied backgrounds and areas of expertise both within and outside of the medical device industry, said Fred Khosravi, CEO and Chairman of Imperative Care.
  • Henrietta Fore joins the companys Board with more than four decades of public service in a variety of sectors.
  • Imperative Care is working to provide a complete solution that increases access to patient care, improves stroke treatment, and helps patients return to their daily activities, said Fore.

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Leadership, Johns Hopkins University, RNA, IND, Therapy, Amylin Pharmaceuticals, Peripheral nervous system, Fellow, Preclinical development, Pharmacology, NDA, Diplomate of National Board, American Board of Commissioners for Foreign Missions, Army Medical Department (United States), Oligonucleotide, UCB, Management, Pharmaceutical industry, Toxicology

ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.

Key Points: 
  • ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.
  • Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals and Senior Director, Preclinical Development at La Jolla Pharmaceuticals.
  • He also had increasing roles of responsibility in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Medical Department.
  • ADARx Pharmaceuticals, Inc. , located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics.